No products in the cart.
Pre-made Milatuzumab benchmark antibody ( Whole mAb, anti-CD74 therapeutic antibody, Anti-CLIP/DHLAG/HLADG/II/Ia-GAMMA/p33 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-344
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Milatuzumab biosimilar, Whole mAb, Anti-CD74 Antibody: Anti-CLIP/DHLAG/HLADG/II/Ia-GAMMA/p33 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Milatuzumab (or hLL1) is an anti-CD74 humanized monoclonal antibody for the treatment of multiple myeloma non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.
| Products Name (INN Index) | Pre-Made Milatuzumab biosimilar, Whole mAb, Anti-CD74 Antibody: Anti-CLIP/DHLAG/HLADG/II/Ia-GAMMA/p33 therapeutic antibody |
|---|---|
| INN Name | Milatuzumab |
| Target | CD74 |
| Format | Whole mAb ADC |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2007 |
| Year Recommended | 2008 |
| Companies | Immunomedics |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Graft-versus-host disease,Haematological malignancies,Chronic lymphocytic leukaemia,Multiple myeloma,Non-Hodgkin's lymphoma,Systemic lupus erythematosus |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD74 |
| Package |
Previous slide
Next slide
